中国肺癌杂志
中國肺癌雜誌
중국폐암잡지
CHINESE JOURNAL OF LUNG CANCER
2013年
8期
427-432
,共6页
二甲双胍%抗肿瘤机制%腺苷酸活化蛋白激酶(AMPK)%代谢%细胞周期阻滞%氧化应激%肿瘤干细胞转化
二甲雙胍%抗腫瘤機製%腺苷痠活化蛋白激酶(AMPK)%代謝%細胞週期阻滯%氧化應激%腫瘤榦細胞轉化
이갑쌍고%항종류궤제%선감산활화단백격매(AMPK)%대사%세포주기조체%양화응격%종류간세포전화
Metformin%Antitumor mechanism%Adenosine monophosphate-activated protein kinase (AMPK)%Metabolism%Cell cycle arrest%Oxidative stress%Transformation of cancer/tumor stem cells
二甲双胍是一种传统的口服降糖药，临床上普遍用于2型糖尿病的治疗。近年来大量流行病学研究报道二甲双胍能够降低2型糖尿病患者的肿瘤发病率，亦有研究发现二甲双胍能在代谢途径、细胞周期、氧化应激、肿瘤干细胞转化等方面通过激活腺苷酸活化蛋白激酶（adenosine monophosphate-activated protein kinase, AMPK）信号通路，从而抑制肿瘤细胞的生长、增殖以及转化。但二甲双胍通过激活AMPK的抗肿瘤机制仍存在着争议，其确切的作用机制有待进一步深入的研究，同时亟需大规模的临床试验来证实。
二甲雙胍是一種傳統的口服降糖藥，臨床上普遍用于2型糖尿病的治療。近年來大量流行病學研究報道二甲雙胍能夠降低2型糖尿病患者的腫瘤髮病率，亦有研究髮現二甲雙胍能在代謝途徑、細胞週期、氧化應激、腫瘤榦細胞轉化等方麵通過激活腺苷痠活化蛋白激酶（adenosine monophosphate-activated protein kinase, AMPK）信號通路，從而抑製腫瘤細胞的生長、增殖以及轉化。但二甲雙胍通過激活AMPK的抗腫瘤機製仍存在著爭議，其確切的作用機製有待進一步深入的研究，同時亟需大規模的臨床試驗來證實。
이갑쌍고시일충전통적구복강당약，림상상보편용우2형당뇨병적치료。근년래대량류행병학연구보도이갑쌍고능구강저2형당뇨병환자적종류발병솔，역유연구발현이갑쌍고능재대사도경、세포주기、양화응격、종류간세포전화등방면통과격활선감산활화단백격매（adenosine monophosphate-activated protein kinase, AMPK）신호통로，종이억제종류세포적생장、증식이급전화。단이갑쌍고통과격활AMPK적항종류궤제잉존재착쟁의，기학절적작용궤제유대진일보심입적연구，동시극수대규모적림상시험래증실。
Metformin, as a traditional oral hypoglycemic agent, is commonly used in the clinical treatment for type 2 diabetes. Recently, a large number of epidemiological researches have shown that metformin could reduce the tumor morbidity of type 2 diabetes, moreover, it has also been indicated that metformin could inhibit the growth, proliferation and transformation of cancer cells in metabolic pathways, cell cycle, oxidative stress and cancer/tumor stem cells transformation via AMPK pathway activation. But the antitumor effect of metformin via AMPK activation still exists arguments, and the deifnite mechanism remains to be further investigated and conifrmed by extensive clinical trials.
